Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation
Protected T-cells persist and proliferate in HIV gene therapy study
Raltegravir has the edge over two protease inhibitors in three-drug comparison study
The 'Boston patients' experience HIV rebound after stem cell transplants
Younger women not at higher risk of HIV from relationships with older men, South African study finds
Self-testing encourages very high uptake of HIV testing in Malawi study
Male life expectancy nine years shorter due to lower male uptake of HIV treatment in rural South Africa
Raltegravir plus boosted darunavir shown to be safe and effective for first-line ART
HIV attachment inhibitor BMS-663068 shows good safety and efficacy in phase 2b study
Maternal deaths due to HIV not declining despite PMTCT successes in South Africa
HIV incidence at record high in young gay black men in southern USA
People with HIV more likely to die after diagnosis of many common cancers in US
Monkey studies confirm viability of injectable PrEP drug
Sofosbuvir & ribavirin cures 75% of genotype 1 HIV/HCV co-infected patients
AbbVie '3D' combination cures 99% of genotype 1b hepatitis C
Simeprevir cures almost 80% of first-time co-infected hepatitis C patients
Faldaprevir plus interferon and ribavirin cures hepatitis C in most people with HIV/HCV co-infection
Six-week oral treatment can cure hard-to-treat hepatitis C patients
